Shares Outstanding Shares Outstanding n/a Close	6.8M
Shares Change (YoY) Shares Change (YoY) n/a Close	19.47%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	1.72%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	21.92%
Shares Floating Shares Floating n/a Close	3.36M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	109
FTD / Avg. Volume FTD / Avg. Volume n/a Close	0.18%

Short Selling Information

The latest short interest is 367.4K, so 6.16% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	367.4K
Short % of Shares Out Short % of Shares Out n/a Close	6.16%
Short % of Float Short % of Float n/a Close	7.82%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	4.8

Valuation Ratios

The PE ratio is -1.17 and the forward PE ratio is -6.54. Atara Biotherapeutics's PEG ratio is 0.01.

PE Ratio PE Ratio n/a Close	-1.17
Forward PE Forward PE n/a Close	-6.54
PS Ratio PS Ratio n/a Close	0.77
Forward PS Forward PS n/a Close	0.3
PB Ratio PB Ratio n/a Close	-1.02
P/FCF Ratio P/FCF Ratio n/a Close	-1.45
PEG Ratio PEG Ratio n/a Close	0.01

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Atara Biotherapeutics.

EV / Sales EV / Sales n/a Close	n/a
EV / EBITDA EV / EBITDA n/a Close	n/a
EV / EBIT EV / EBIT n/a Close	n/a
EV / FCF EV / FCF n/a Close	n/a

Financial Position

The company has a current ratio of 0.48, with a Debt / Equity ratio of -0.45.

Current Ratio Current Ratio n/a Close	0.48
Quick Ratio Quick Ratio n/a Close	0.4
Debt / Equity Debt / Equity n/a Close	-0.45
Debt / EBITDA Debt / EBITDA n/a Close	-0.58
Debt / FCF Debt / FCF n/a Close	-0.64
Interest Coverage Interest Coverage n/a Close	-18.08

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity Return on Equity n/a Close	n/a
Return on Assets Return on Assets n/a Close	n/a
Return on Invested Capital Return on Invested Capital n/a Close	n/a
Revenue Per Employee Revenue Per Employee n/a Close	$842,745.1
Profits Per Employee Profits Per Employee n/a Close	$-558,189.54
Employee Count Employee Count n/a Close	153
Asset Turnover Asset Turnover n/a Close	1.18
Inventory Turnover Inventory Turnover n/a Close	1.97

Taxes

Income Tax Income Tax n/a Close	-12K
Effective Tax Rate Effective Tax Rate n/a Close	0.01%

Stock Price Statistics

The stock price has increased by -31.53% in the last 52 weeks. The beta is 0.18, so Atara Biotherapeutics's price volatility has been higher than the market average.

Beta Beta n/a Close	0.18
52-Week Price Change 52-Week Price Change n/a Close	-31.53%
50-Day Moving Average 50-Day Moving Average n/a Close	7.21
200-Day Moving Average 200-Day Moving Average n/a Close	8.82
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	62.87
Average Volume (20 Days) Average Volume (20 Days) n/a Close	59,049

Income Statement

In the last 12 months, Atara Biotherapeutics had revenue of 128.94M and earned -85.4M in profits. Earnings per share was -11.41.

Revenue Revenue n/a Close	128.94M
Gross Profit Gross Profit n/a Close	107.93M
Operating Income Operating Income n/a Close	-83.44M
Net Income Net Income n/a Close	-85.4M
EBITDA EBITDA n/a Close	-75.75M
EBIT EBIT n/a Close	-80.8M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	-11.41

Full Income Statement

Balance Sheet

The company has 25.03M in cash and 43.83M in debt, giving a net cash position of -18.8M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	25.03M
Total Debt Total Debt n/a Close	43.83M
Net Cash Net Cash n/a Close	-18.8M
Retained Earnings Retained Earnings n/a Close	-2.05B
Total Assets Total Assets n/a Close	62.04M
Working Capital Working Capital n/a Close	-20.71M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -68.72M and capital expenditures -246K, giving a free cash flow of -68.96M.

Operating Cash Flow Operating Cash Flow n/a Close	-68.72M
Capital Expenditures Capital Expenditures n/a Close	-246K
Free Cash Flow Free Cash Flow n/a Close	-68.96M
FCF Per Share FCF Per Share n/a Close	-9.21

Full Cash Flow Statement

Margins

Gross margin is 83.71%, with operating and profit margins of -64.71% and -66.23%.

Gross Margin Gross Margin n/a Close	83.71%
Operating Margin Operating Margin n/a Close	-64.71%
Pretax Margin Pretax Margin n/a Close	-66.24%
Profit Margin Profit Margin n/a Close	-66.23%
EBITDA Margin EBITDA Margin n/a Close	-58.75%
EBIT Margin EBIT Margin n/a Close	-64.71%
FCF Margin FCF Margin n/a Close	-53.48%

Dividends & Yields

ATRA does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	n/a
FCF Yield FCF Yield n/a Close	n/a

Dividend Details

Analyst Forecast

The average price target for ATRA is $17.5, which is 100% higher than the current price. The consensus rating is "Buy".

Price Target Price Target n/a Close	$17.5
Price Target Difference Price Target Difference n/a Close	100%
Analyst Consensus Analyst Consensus n/a Close	Buy
Analyst Count Analyst Count n/a Close	5

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	n/a
Graham Upside Graham Upside n/a Close	n/a

Stock Splits

The last stock split was on Jun 20, 2024. It was a backward split with a ratio of 1:25.

Last Split Date Last Split Date n/a Close	Jun 20, 2024
Split Type Split Type n/a Close	backward
Split Ratio Split Ratio n/a Close	1:25

Scores

Altman Z-Score Altman Z-Score n/a Close	-44.57
Piotroski F-Score Piotroski F-Score n/a Close	2